messag believ remain one best-posit large-cap compani
healthcar servic given uniqu collect asset solid
earn beat total ebit rose nearli like impend closur
aet transact highlight superior posit bottom line greater control
larger number patient live combin entiti drive broad-bas share gain
lower cost capital-light natur aet busi enabl
rapidli de-lever share trade ebitda maintain
buy rate pt
spearhead pbm top-lin overhead cost top consensu
ep expect one largest beat past sever year
detail exhibit out-performance larg driven stronger top-lin
pbm segment stabl retail segment slightli ahead plan shown exhibit
retail ebit line forecast rise back profit rx growth
good cost control pbm ebit declin lesser due million revenu beat
modestli better gross margin see exhibit corpor overhead benefit last
momentum slow guidanc appear conserv despit beat
midpoint full-year guidanc rais updat guidanc call
ebit revers growth declineon time labor
invest retail segment new account on-board cost within pbm
howev solid top-lin modest gross margin eros believ guidanc
remain conserv actual rais full-year ep estim
high end rang although aet key near-term catalyst on-going
earn upsid signific well
aet closur loom aheaddivestitur like immateri note expect
aet transact close late september/earli octob two month away
doj approv last signific hurdl clear aftermath ts feder court victori
vertic acquisit time warner success complet aet merger
seem plausibl could modest divestitur d-relat asset per
compani would materi busi strongli believ
closur transact serv catalyst share give
complet collect asset space
omnicar stumbl diminish asset integr pedigre speak
acquisit also took billion goodwil impair write-down connect
purchas omnicar rare manag stumbl come
asset integr howev chalk difficult skill nurs end market
less-than-optim servic model around assist independ live segment
slow respons two issu view aet end market face
challeng boast strong manag team ensur consist execut
believ unlik dent investor confid integr skill set
page analyst certif import disclosur
exhibit solid driven time pbm earn
compani data guggenheim secur llc
page analyst certif import disclosur
guidancemidpoint guidanceactualbeat miss guidancemidpoint guidanceactualbeat mid-high guidanceactualbeat miss guidancemidpoint guidanceactualbeat guidanceactualbeat miss guidancemidpoint guidanceactualbeat na segment averagequartersal growthebit growth averagetot compani quartersal growthepspharmaci servic segment quartersal growthebit growth averag drug store
compani data guggenheim secur llc
page analyst certif import disclosur
y/i end y/i pharmaci front y/i y/i cmx compani y/i cog gross y/i bp gross y/i bp gross y/i bp gross y/i bp y/i y/i elimin y/i compani y/i y/i expens y/i expens elimin y/i y/i expens y/i ebit y/i ebit elimin ic y/i y/i ebit y/i ebitda expens y/i tax y/i back amort nci incom alloc particip net y/i usd million except drug store
compani data guggenheim secur llc
page analyst certif import disclosur
find valuat attract rel consum peer share trade ep
ebitda current price-to-earnings multipl five-year histor averag abil deliv excess
billion free cash flow plu opportun associ pend aet acquisit stand among larg cap
retail/healthcar peer price target base price-to-earnings multipl ep impli upsid potenti
current level
primari risk thesi signific contract loss caremark would compromis busi
turnaround greater-than-expect pharmaci reimburs pressur would dampen bottom-lin benefit gener
boom intens retail promot price environ would limit ebit margin expans
page analyst certif import disclosur
quarterli annual incom statement decemb year-end
cmx sale
ic sale
less nci incom alloc particip secur
compani data guggenheim secur llc
page analyst certif import disclosur
quarterli annual incom statement decemb year-end
compani data guggenheim secur llc
page analyst certif import disclosur
